engleski

ANALYSIS OF OVERALL SURVIVAL IN PATIENTS WITH LUNG CANCER BEFORE THE INTRODUCTION OF TYROSINE KINASE INHIBITORS AND IMMUNOTHERAPY IN THE REPUBLIC OF CROATIA – A SINGLE INSTITUTION STUDY

We analyzed outcome in patients with lung cancer (LC) in the period before the introduction of tyrosine kinase inhibitors and immunotherapy in the Republic of Croatia in comparison to similar studies abroad and created a basis for future analysis. At the Pathology Department, Split University Hospital Center, 1165 patients were diagnosed with LC during the 2012-2016 period. Data on age, gender, biopsy specimen, histologic type, and stage of disease were collected. Overall survival of each patient was calculated from the date of biopsy until death or the last day of follow-up.There were 74% of male and 26% of female patients. Median age was 66 years, younger than in other similar studies. In 78% of patients, the diagnosis of LC was based on brochoscopic biopsy. Adenocarcinoma (ADC) was diagnosed in 42.9%, squamous cell carcinoma (SCC) in 32.7%, and small cell lung carcinoma (SCLC) in 16.7% of cases. In females, ADC was more common than SCC (p<0.001). The mean survival was 22.3 months, median 10 months, and 5-year survival rate was 16.5%. Patients older than 74 years had shorter mean survival compared to younger patients, with the risk of death 1.1 times higher for each increasing age range group (p<0.001). The risk of death was 1.34 times higher in males than females (p<0.001), and 1.12 times higher for SCLC than ADC/SC (p=0.005). Gender, age, and histologic type were confi rmed as independent prognostic factors. Women lived on average 8 months longer than men (28 vs. 20.4 months). The 5-year survival rate of 16.5% in the Split-Dalmatia County was better than the one recorded at the national level (10%).

lung cancer ; overall survival ; personalised therapy ; Croatia

nije evidentirano